There was a significant difference in immune and stromal scores between glioma cases with low and high TNFRSF19 expression levels, with higher scores seen in individuals with high TNFRSF19 expression across all four cohorts (P < 0.001, Fig. 6E–H). This evidence concerns the gene TNFRSF19 and central nervous system cancer.